03:25 PM EDT, 10/22/2024 (MT Newswires) -- Nexalin Technology ( NXL ) shares rose 15% in recent trading Tuesday after the company announced a planned clinical trial for its Gen-3 Halo headset to treat victims of traumatic brain injury.

The trial is in collaboration with the University of California, San Diego, the company said Tuesday in a statement.

The headset will be used in a virtual clinic model, and the trial will evaluate the effectiveness of the device on brain activity and symptom relief in veterans with mild traumatic brain injury, the company said.

Price: 1.71, Change: +0.23, Percent Change: +15.54